Table 1.

Univariate analysis of pharmacokinetic parameters and biological or clinical variables

		CL(L/day)	Kout (day-1)	V1(L)	V2(L)
	n	p
Age	44	0.86	0.82	0.90	0.99
Sex male versus female	23 versus 21	0.59	0.53	0.34	0.37
Body surface area (BSA, m2)	44	0.59	0.82	0.76	0.99
Binet stage A or B versus C	27 versus 17	0.89	0.82	0.34	0.99
Treatment RB versus RFC	17 versus 28	0.48	0.82	0.76	0.99
Lymphocytosis	44	0.59	0.30	0.96	0.99
Areas of lymphadenopathy	44	0.59	0.39	0.96	0.51
CD38 positivity (≥30%) versus negativity	21 versus 22	0.88	0.82	0.90	0.99
FCGR F/F versus V/F and V/V	25 versus 19	0.86	0.68	0.90	0.99
IGHV unmutated versus mutated status	10 versus 6	0.37	0.82	0.96	0.99
Cytogenetics
Isolated del(13q) versus others	8 versus 36	0.37	0.02	0.76	0.23
Trisomy 12 versus others	10 versus 34	0.59	0.92	0.76	0.37
Normal caryotype versus others	4 versus 40	0.89	0.39	0.96	0.66
Del(11q) versus others	10 versus 34	0.37	0.17	0.76	0.17
Del(17p) versus others	9 versus 35	0.17	0.007	0.17	0.23
Time to relapse (TTR)	44	0.59	0.82	0.96	0.99
Time to second treatment (TST)	44	0.37	0.39	0.96	0.99

vs. versus, CL clearance, Kout first-order rate constant of rituximab independent death of latent target antigen, V1 central distribution volume, V2 peripheral distribution volume, RB rituximab bendamustine, RFC rituximab fludarabine cyclophosphamide, FCGR Fc gamma receptor, IGHV immunoglobulin heavy chain variable region. Values were adjusted for multiple testing using the Benjamini–Hochberg method (https://www.sdmproject.com/utilities/?show=FDR), and p < 0.05 considered as significant